Ruxandra Draghia-Akli
EVP, Research & Development · NOVAVAX INC
Individual
- 2024
- Mar 9, 2026
- 4
Other insiders active in the same sector
No other insider has filed at Ruxandra Draghia-Akli's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- Paul A. Mahon - $98.96M in UTHR purchases and sales in the last 12 months
- Herriot Tabuteau - $97.80M in AXSM purchases and sales in the last 12 months
- TCO GROUP HOLDINGS, L.P. - $92.50M in INNV purchases and sales in the last 12 months
- IGNITE AGGREGATOR LP - $92.50M in INNV purchases and sales in the last 12 months
- SUVRETTA CAPITAL MANAGEMENT, LLC - $90.98M in MANE purchases and sales in the last 12 months
- Steven Leonard Chapman - $89.87M in NTRA purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Ruxandra Draghia-Akli?
Ruxandra Draghia-Akli is a corporate insider, tracked as EVP, Research & Development of NOVAVAX INC (NVAX). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Ruxandra Draghia-Akli last file a Form 4?
The most recent primary Form 4 on record is dated 9 March 2026, one of 4 filings going back to 2024.
